Juan Vasquez, MD

Noronha K, Lucas K, Zhao S, Edmonds J, Friedman S, Murray M, Liu S, Liang J, Paradkar S, Zeng H, Sundaram R, Spurrier J, Raponi M, Sajed D, Shuch B, Vasquez J, Bindra R. Abstract 3086: NAPRT silencing in oncometabolite-producing cancers confers therapeutic vulnerabilities to NAD+ depletion. Cancer Research 2024, 84: 3086-3086. DOI: 10.1158/1538-7445.am2024-3086.

Zhao S, Noronha K, Bhardwaj P, Lucas K, Sundaram R, Heer C, Morotti R, Spurrier J, Raponi M, Bindra R, Vasquez J. Abstract 2866: NAPRT silencing in rhabdomyosarcoma confers therapeutic vulnerabilities to NAD+depletion. Cancer Research 2024, 84: 2866-2866. DOI: 10.1158/1538-7445.am2024-2866.

Lee T, Bhatt D, Sundaram R, Saltzman W, Bindra R, Vasquez J. MODL-02. DEVELOPMENT OF RODENT GLIOBLASTOMA MODELS OF MGMT-MEDIATED TEMOZOLOMIDE RESISTANCE. Neuro-Oncology 2023, 25: v298-v298. PMCID: PMC10640218, DOI: 10.1093/neuonc/noad179.1153.

Xu S, Campbell A, Chiang V, Bindra R, Vasquez J, Pashankar F. Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors. Pediatric Blood & Cancer 2023, 70: e30303. PMID: 36975152, DOI: 10.1002/pbc.30303.

Vasquez J, Luo L, Hiniker S, Rhee D, Dasgupta R, Chen S, Weigel B, Xue W, Venkatramani R, Arndt C. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatric Blood & Cancer 2023, 70: e30293. PMID: 36916768, PMCID: PMC10424503, DOI: 10.1002/pbc.30293.

Gueble SE, Vasquez JC, Bindra RS. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Current Treatment Options In Oncology 2022, 23: 1566-1589. PMID: 36242713, DOI: 10.1007/s11864-022-01024-5.

Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide. Pediatric Blood & Cancer 2022, 70: e30020. PMID: 36151992, DOI: 10.1002/pbc.30020.

Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Oncotarget 2022, 13: 1054-1067. PMID: 36128328, PMCID: PMC9477221, DOI: 10.18632/oncotarget.28273.

Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular Cancer Therapeutics 2022, 21: 1090-1102. PMID: 35439320, PMCID: PMC9256811, DOI: 10.1158/1535-7163.mct-21-1000.

Ueno D, Sule A, Liang J, van Doorn J, Sundaram R, Caliliw R, Ye H, Huang R, Li J, Boyd K, Bindra R, Vasquez J, Shuch B. Abstract P055: Targeting Krebs-cycle-deficient renal cell carcinoma with PARP inhibitor and low-dose alkylating chemotherapy. Molecular Cancer Therapeutics 2021, 20: p055-p055. DOI: 10.1158/1535-7163.targ-21-p055.

Gayle S, Vasquez J, Paradis T, Jones K, Sundaram R, van Doorn J, Muthusamy V, Bindra R, Aiello R, Paralkar V. Abstract P258: CBX-12 (alphalexTM-exatecan) sensitizes tumors to immune checkpoint blockade in an antigen agnostic manner by immune activation. Molecular Cancer Therapeutics 2021, 20: p258-p258. DOI: 10.1158/1535-7163.targ-21-p258.

Sule A, Van Doorn J, Sundaram RK, Ganesa S, Vasquez JC, Bindra RS. Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. NAR Cancer 2021, 3: zcab018. PMID: 34027408, PMCID: PMC8127964, DOI: 10.1093/narcan/zcab018.

Bailur JK, McCachren SS, Pendleton K, Vasquez JC, Lim H, Duffy A, Doxie D, Kaushal A, Foster C, DeRyckere D, Castellino S, Kemp ML, Qiu P, Dhodapkar M, Dhodapkar K. Risk associated alterations in marrow T cells in pediatric leukemia. JCI Insight 2020, 5: e140179. PMID: 32692727, PMCID: PMC7455136, DOI: 10.1172/jci.insight.140179.

Robinson MH, Vasquez J, Kaushal A, MacDonald TJ, Vega J, Schniederjan M, Dhodapkar K. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal For ImmunoTherapy Of Cancer 2020, 8: e001066. PMID: 32788236, PMCID: PMC7422651, DOI: 10.1136/jitc-2020-001066.

Hong CS, Vasquez JC, Kundishora AJ, Elsamadicy AA, Beckta JM, Sule A, Marks AM, Leelatian N, Huttner A, Bindra RS, DiLuna ML, Kahle KT, Erson-Omay EZ. Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma. Npj Genomic Medicine 2020, 5: 23. PMID: 32528726, PMCID: PMC7264170, DOI: 10.1038/s41525-020-0130-7.

McNerney KO, Vasquez JC, Kent MW, McNamara JM. Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report. Journal Of Pediatric Hematology/oncology 2017, 39: e454-e455. PMID: 28085749, DOI: 10.1097/MPH.0000000000000776.

Vasquez JC, Huttner A, Zhang L, Marks A, Chan A, Baehring JM, Kahle KT, Dhodapkar KM. SOX2 immunity and tissue resident memory in children and young adults with glioma. Journal Of Neuro-Oncology 2017, 134: 41-53. PMID: 28620836, PMCID: PMC7906294, DOI: 10.1007/s11060-017-2515-8.

Vasquez J, Huttner A, Zhang L, Marks A, Chan A, Baehring J, Kahle K, Dhodapkar K. SOX2 as a target for immunotherapy of pediatric gliomas. Journal Of Clinical Oncology 2017, 35: e22012-e22012. DOI: 10.1200/jco.2017.35.15_suppl.e22012.

Boddupalli CS, Nair S, Gray SM, Nowyhed HN, Verma R, Gibson JA, Abraham C, Narayan D, Vasquez J, Hedrick CC, Flavell RA, Dhodapkar KM, Kaech SM, Dhodapkar MV. ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. Journal Of Clinical Investigation 2016, 126: 3905-3916. PMID: 27617863, PMCID: PMC5096804, DOI: 10.1172/jci85329.

Das R, Sehgal K, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar K, Dhodapkar M. Abstract 1354: Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets. 2015, 1354-1354. DOI: 10.1158/1538-7445.am2015-1354.

Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.